You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Theranostic

Showing 1 - 25 of 73
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Prostate Cancer Trial in Houston (177Lu rhPSMA-10.1, Degarelix)

Not yet recruiting
  • Prostate Cancer
  • Houston, Texas
    M D Anderson Cancer Center
Sep 27, 2023

STARD3 in Colorectal Cancer: The STAR Study

Recruiting
  • Colorectal Cancer
    • Aviano, Pordenone, Italy
      Centro di Riferimento Oncologico (CRO) di Aviano - IRCCS
    Nov 16, 2023

    Ultra-rapid BRCA1/2 Status Screening Test in Theranostic

    Not yet recruiting
    • Breast Cancer
    • Questionnaires
    • Communication of the results of the BRCA1/2 ultra rapid test
    • (no location specified)
    Oct 26, 2023

    Neuroendocrine Tumors, Prostate Cancer Trial in Salt Lake City (Single-Tracer FDG PET/CT Exam, Single-Tracer Cu64-DOTATATE

    Recruiting
    • Neuroendocrine Tumors
    • Prostate Cancer
    • Single-Tracer FDG PET/CT Exam
    • +3 more
    • Salt Lake City, Utah
      Huntsman Cancer Institute
    Dec 27, 2022

    Keratoconus Trial in Catanzaro, Firenze, Messina (Riboflavin/UV-A corneal cross-linking)

    Recruiting
    • Keratoconus
    • Riboflavin/UV-A corneal cross-linking
    • Catanzaro, Italy
    • +2 more
    Jul 13, 2022

    Metastatic Pancreatic Cancer, Locally Advanced Pancreatic Adenocarcinoma Trial in Sacramento ([68Ga]Ga DOTA-5G and [177Lu]Lu

    Recruiting
    • Metastatic Pancreatic Cancer
    • Locally Advanced Pancreatic Adenocarcinoma
    • [68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G.
    • Sacramento, California
      University of California Davis
    Apr 21, 2022

    Malignant Brain Tumors Trial in Berkel en Rodenrijs (procedure, device, other)

    Recruiting
    • Malignant Brain Tumors
    • intra-arterial injection
    • +2 more
    • Berkel en Rodenrijs, Zuid Holland, Netherlands
      Laurens Groenendijk
    Apr 3, 2023

    Clinical Relevance of PSMA Expression in Malignant Gastrointestinal Tumors Trial in Wuerzburg (18F-PSMA PET/CT)

    Recruiting
    • Clinical Relevance of PSMA Expression in Malignant Gastrointestinal Neoplasms
    • 18F-PSMA PET/CT
    • Wuerzburg, Bavaria, Germany
      University Hospital Wuerzburg
    Sep 15, 2022

    Breast Cancer Trial in Sydney ([68Ga]GA-NeoB)

    Recruiting
    • Breast Cancer
    • Sydney, New South Wales, Australia
      St Vincent's Hospital
    May 22, 2023

    Prostate Cancer Trial in St Leonards, Perth (177Lu-DOTA-TLX591)

    Not yet recruiting
    • Prostate Cancer
    • 177Lu-DOTA-TLX591
    • St Leonards, New South Wales, Australia
    • +1 more
    Jul 18, 2022

    177Lu-DOTA-FAPI, 68Ga-DOTA-FAPI, Theranostic Trial in XiaMen (68Ga-DOTA-FAPI, 177Lu-DOTA-FAPI)

    Recruiting
    • 177Lu-DOTA-FAPI
    • +2 more
    • 68Ga-DOTA-FAPI, 177Lu-DOTA-FAPI
    • XiaMen, Fujian, China
      First affiliated hospital of xiamen university
    Apr 15, 2021

    Prostatic Tumors, Castration-Resistant Trial (64Cu-SAR-BBN, 67Cu-SAR-BBN)

    Not yet recruiting
    • Prostatic Neoplasms
    • Castration-Resistant
    • (no location specified)
    Dec 1, 2022

    Corona Virus Disease 2019 (COVID-19) Trial in Lahore (Tocilizumab)

    Completed
    • Corona Virus Disease 2019 (COVID-19)
    • Lahore, Punjab, Pakistan
      The University of Lahore
    Dec 30, 2020

    Prostatic Tumors, Castration-Resistant Trial in United States (64Cu-SAR-bisPSMA, 67Cu-SAR-bisPSMA)

    Recruiting
    • Prostatic Neoplasms, Castration-Resistant
    • Phoenix, Arizona
    • +6 more
    May 23, 2022

    Neuroblastoma, Relapsed Neuroblastoma, Refractory Neuroblastoma Trial in United States (67Cu-SARTATE, 64Cu-SARTATE)

    Recruiting
    • Neuroblastoma
    • +2 more
    • Phoenix, Arizona
    • +8 more
    Jun 29, 2022

    Glioblastoma, Molecular Disease Trial in Amiens (Correlation between molecular anomalies of the primary tumor and circulating

    Terminated
    • Glioblastoma
    • Molecular Disease
    • Correlation between molecular anomalies of the primary tumor and circulating tumor DNA
    • Amiens, Picardie, France
      CHU Amiens Picardie
    Jul 13, 2020

    Lung Tumors Trial in France (ALK analysis on CTCs detected by ISET)

    Completed
    • Lung Neoplasms
    • ALK analysis on CTCs detected by ISET
    • Caen, France
    • +10 more
    Dec 7, 2020

    Hepatocarcinoma, Pancreatic Tumor Trial in Clichy (Hepatocellular carcinoma, Pancreatic adenocarcinoma, Pancreatic

    Recruiting
    • Hepatocarcinoma
    • Pancreatic Tumor
    • Hepatocellular carcinoma
    • +2 more
    • Clichy, France
      Hôpital Beaujon
    Mar 20, 2023

    Meningioma Trial in Sydney (Cu-64 SARTATE and Cu-67 SARTATE)

    Completed
    • Meningioma
    • Cu-64 SARTATE and Cu-67 SARTATE
    • Sydney, New South Wales, Australia
      Royal North Shore Hospital
    Apr 16, 2020

    COVID-19 Trial (Blood sample collection, Saliva sample collection, Nasopharyngeal and nasal sample collection)

    Not yet recruiting
    • COVID-19
    • Blood sample collection
    • +3 more
    • (no location specified)
    May 12, 2023

    Glioma, Malignant Trial in London (PET-MRI, Brain tumour biopsy)

    Not yet recruiting
    • Glioma, Malignant
    • PET-MRI
    • Brain tumour biopsy
    • London, United Kingdom
      King's College London
    Jun 8, 2022

    Medullary Thyroid Carcinoma Trial in Worldwide (111In-CP04, 111In-CP04 with co-administration of gelofusine/gelaspan)

    Completed
    • Medullary Thyroid Carcinoma
    • 111In-CP04
    • 111In-CP04 with co-administration of gelofusine/gelaspan
    • Innsbruck, Austria
    • +4 more
    Mar 19, 2020

    Theranostic Test to PREDict Treatment Response of Anti-TNFa

    Terminated
    • RheumatoId Arthritis
    • Infliximab
    • +6 more
    • Prague, Czechia
    • +7 more
    Dec 21, 2019

    Patients With Metastatic Castration-resistant Prostate Cancer Trial (177Lu-PSMA-617 PET scan)

    Not yet recruiting
    • Patients With Metastatic Castration-resistant Prostate Cancer
    • 177Lu-PSMA-617 PET scan
    • (no location specified)
    Nov 13, 2023

    Tumor, Solid Trial in Beijing (68Ga-DOTA-F2 PET/CT and 18F-FDG)

    Recruiting
    • Tumor, Solid
    • 68Ga-DOTA-F2 PET/CT and 18F-FDG
    • Beijing, Beijing, China
      Peking union medical college hospital
    Nov 27, 2022